Amphipathic Cell-Penetrating Peptide-Aided Delivery of Cas9 RNP for In Vitro Gene Editing and Correction
Pharmaceutics · 20.10.2023 · 15 (10) · 2500
DOI: 10.3390/pharmaceutics15102500 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 20.10.2023. Verfasst von Mert Öktem und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, The Neth…. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Turkish Ministry of Education, Türkiye Ministry of National Education.
Abstract (Originalsprache)
The therapeutic potential of the CRISPR-Cas9 gene editing system in treating numerous genetic disorders is immense. To fully realize this potential, it is crucial to achieve safe and efficient delivery of CRISPR-Cas9 components into the nuclei of target cells. In this study, we investigated the applicability of the amphipathic cell-penetrating peptide LAH5, previously employed for DNA delivery, in the intracellular delivery of spCas9:sgRNA ribonucleoprotein (RNP) and the RNP/single-stranded homology-directed repair (HDR) template. Our findings reveal that the LAH5 peptide effectively formed nanocomplexes with both RNP and RNP/HDR cargo, and these nanocomplexes demonstrated successful cellular uptake and cargo delivery. The loading of all RNP/HDR components into LAH5 nanocomplexes was confirmed using an electrophoretic mobility shift assay. Functional screening of various ratios of peptide/RNP nanocomplexes was performed on fluorescent reporter cell lines to assess gene editing and HDR-mediated gene correction. Moreover, targeted gene editing of the CCR5 gene was successfully demonstrated across diverse cell lines. This LAH5-based delivery strategy represents a significant advancement toward the development of therapeutic delivery systems for CRISPR-Cas-based genetic engineering in in vitro and ex vivo applications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands.
ORCID-Profile: Mert Öktem, Olivier G de Jong
Förderung
- Turkish Ministry of Education
- Türkiye Ministry of National Education
Zitieren
APA
Öktem, M., Mastrobattista, E., & de Jong, O. G. (2023). Amphipathic Cell-Penetrating Peptide-Aided Delivery of Cas9 RNP for In Vitro Gene Editing and Correction. Pharmaceutics, 15(10), 2500. https://doi.org/10.3390/pharmaceutics15102500
Vancouver
Öktem M, Mastrobattista E, de Jong OG. Amphipathic Cell-Penetrating Peptide-Aided Delivery of Cas9 RNP for In Vitro Gene Editing and Correction. Pharmaceutics. 2023;15(10):2500. doi:10.3390/pharmaceutics15102500
BibTeX
@article{ktem2023,
author = {Öktem, Mert and Mastrobattista, Enrico and de Jong, Olivier G},
title = {Amphipathic Cell-Penetrating Peptide-Aided Delivery of Cas9 RNP for In Vitro Gene Editing and Correction},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {10},
pages = {2500},
doi = {10.3390/pharmaceutics15102500}
}
EUVIMED